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A 41-year-old woman with autosomal dominant polycystic kidney disease had chronic kidney disease class IV. She presented
10 days postpartum with a 4-day history of severe hematuria, left ﬂank pain, and anemia, hemoglobin 62g/L. CT scan showed
massively enlarged kidneys with multiple cysts; several cysts bilaterally had high attenuation consistent with hemorrhage.
Hematuria persisted over several days despite intensive conservative measures that included vitamin K1, 4 units of plasma,
transfusion of 10 units of packed RBCs, Darbopoeitin, and DDAVP. Antiﬁbrinolytic therapy was given with tranexamic acid
1000mg p.o. t.i.d for one day then OD. The hematuria stopped within 24 hours and did not recur after tranexamic acid therapy
ended. Over the next 4 years there were 3 hospitalizations each with severe gross hematuria requiring blood transfusion for acute
anemia. The hematuria responded well to further treatment with tranexamic acid. Tranexamic acid produces antiﬁbrinolytic
eﬀects via complex interactions with plasminogen, displacing plasminogen from the ﬁbrin surface. Chronic renal impairment is
considered arelative contraindicationto useoftranexamicacid due to reports ofureteric clotsandacute renalfailurefrom cortical
necrosis. We conclude that tranexamic acid can be used safely in some patients with CKD and polycystic kidney disease to treat
severe hematuria.
1.Background
Hematuria is a common problem in patients with polycystic
kidney disease (PCKD), with 42% of patients experiencing
at least one episode of gross hematuria [1]. This is usually
controlled with medical therapy and rarely needs surgical
intervention. Although self-limited, cumulative episodes of
gross hematuria may have an unfavorable impact on long-
term renal function [1].
Here we describe a case of recurrent severe hematuria in
PCKD treated successfully on six occasions with tranex-
amic acid (TA), an antiﬁbrinolytic agent that competitively
inhibits the activation of plasminogen to plasmin [2].
2.The Case
A 41-year-old Caucasian woman was diagnosed at age 12
with autosomal dominant PCKD. She presented to the
emergency room 10 days after normal spontaneous vaginal
delivery with a four-day history of gross hematuria and left
ﬂankpain.Shewastakinghydromorphoneforﬂankpainand
labetalol for hypertension. On physical exam she was pale
with hypoxemic O2 saturation 96% on 3L nasal cannula,
and she had fever (38.7) with normal BP and pulse rate
(BP 136/90mmHg. PR94bpm). She had high JVP (6cm
above the sternal angle), normal heart sounds, bilateral
basal crackles on chest examination and markedly enlarged
irregular nontender kidneys.
Urinalysis showed large blood and 3–5WBCs/hpf with
no proteinuria. Hemoglobin was 62g/L from a baseline of
132g/L several months prior. Her electrolytes were normal.
Urea was 16.8mmol/L and creatinine 315µmol/L, eGFR
(MDRD) 15mL/min/1.73m2.I N Rw a s1 . 9 ,P T T ,a n dp l a t e -
lets were normal. Chest X-ray revealed pulmonary edema.
Echocardiogram showed dilated cardiomyopathy with
ejection fraction of 18%. Unenhanced CT scan showed mas-
sively enlarged kidneys with multiple cysts; there were sev-
eral cysts bilaterally with high attenuation consistent with2 International Journal of Nephrology
hemorrhage but no stones, masses, or tumours. MRIshowed
a large hemorrhagic cyst within the left kidney but otherwise
the same ﬁndings as the CT scan. Patient underwent cys-
toscopy, and blood was seen coming from the left ureteric
oriﬁce, with no evidence of obstruction. Renal angiogram
failed to reveal a major bleeding site.
The patient was treated for possible sepsis and urinary
tract infection with intravenous antibiotics: Cefazolin 1gm
every 12 hours, Clindamycin 600mg every 8 hours, and
Ciproﬂoxacin 400mg daily. Blood and urine cultures were
negative, and antibiotics were stopped on the 2nd day of
admission.
The hematuria was managed conservatively with vitamin
K 10mg subcutaneously daily for 5 days, Darbepoietin
80mcg subcutaneously once weekly, plus 4 units of plasma
to correct the coagulopathy. DDAVP 20mcg intravenously
daily was given for 6 days. However gross hematuria
continued, despite daily transfusions of pRBCs total of 10
units. Hemoglobin remained around 70g/L. Consideration
was given to a left nephrectomy.
3.Management
Because of high surgical risk with poor cardiac status and the
long-term impact of nephrectomy on kidney function,
antiﬁbrinolytic therapy was given with TA (Cyklokapron,
Pﬁzer Canada Inc., QC) 11mg/kg (1000mg) orally three
times a day for one day then once daily for 5 days.
The hematuria stopped within 24 hours and did not
recur after TA therapy was stopped. Hemoglobin stabilized
at 95g/L. Kidney function improved; serum creatinine fell to
224µmol/L on discharge.
She presented ﬁve days after discharge with dyspnea and
bilateral lower limb edema and was thought to have a deep
venous thrombosis. She was given Dalteparin 200units/kg
subcutaneously. Doppler ultrasound of the leg veins was
normal but she again developed hematuria which persisted
despite stopping the Dalteparin. She was treated with TA
11mg/kg orally twice a day for one day then once daily for
5 days. The hematuria stopped within 24 hours and did not
recur after TA therapy ended. Serum creatinine was stable
during this admission.
The patient presented 2 years later with a ten-day history
of gross hematuria and left-sided ﬂank pain. She had been
given Co-trimoxazole one DS tablet twice a day for ﬁve
days for presumed urinary tract infection. Hemoglobin was
77g/L, and serum creatinine was 560µmol/L compared with
120g/L and 360µmol/L, respectively, a month before. Coag-
ulation proﬁle was normal, urine grew normal ﬂora, and
Co-trimoxazole was stopped. She was treated conservatively
and received total of 4 units of packed red blood cells,
and DDAVP 20 mcg intravenously daily for 3 doses. The
hematuria continued. TA 15mg/kg was given 3 times a
day for 3 doses then daily for 3 doses. Hematuria stopped
within 24 hours. She developed mild nausea that responded
to Metoclopramide. Hemoglobin stabilized at 100g/L, and
serum creatinine fell to baseline.
Six months later she presented with one-week history of
gross hematuria. Despite Darbepoetin therapy, hemoglobin
had fallen from 111g/L a month before to 76g/L. Serum cre-
atinine rose from 400µmol/L a month prior to 450µmol/L.
She had no ﬂank pain, fever, or urinary symptoms. She was
transfused with 2 units packed red blood cells and given
TA 10mg/kg intravenously daily for 3 doses. The hema-
turia stopped within a day, and she was discharged with
hemoglobin 91g/L and renal function went back to baseline.
Twelve and sixteen months after her last admission, she
presented with painless hematuria and was treated as an out
patient with TA 11mg/kg orally daily, and her hematuria
resolved within 24–36 hours after the ﬁrst dose on both
occasions.
Thepatient progressedtoend-stagerenaldisease andwas
started on hemodialysis four years after the initial presenta-
tion.
4.Discussion
Gross hematuria is a common manifestation of PCKD. It
can result from trauma, renal calculi, tumor, or infection.
Spontaneous cyst bleeding is important to consider in this
particular group of patients; it can be prolonged by local
activation of ﬁbrinolysis by urokinase [3].
The management of hematuria in PCKD is usually con-
servativewithbedrest,bloodtransfusion, correctionofcoag-
ulopathies, use of DDAVP, and erythropoietin stimulating
protein. Nonetheless, other modalities have been tried to
avoid prolonged hospitalization and nephrectomy and to
preserve kidney function. These include other antiﬁbri-
nolytic agents such as aprotinin and epsilon aminocaproic
acid (EACA) [3].
We report rapid cessation of hematuria in PCKD on four
occasions with administration of TA, a potent ﬁbrinolysis
inhibitor. TA or trans-4-(aminomethyl) cyclohexanecarbox-
ylic acid is approximately 10 times more potent in binding
to plasminogen than EACA and is better tolerated [4]. It is a
synthetic amino acid which reversibly blocksthe lysine bind-
ing sites on plasminogen; these are important for binding to
ﬁbrin and subsequent activation by plasminogen activators
and ﬁbrinolysis [5]. In the setting of renal impairment TA
improves platelet function and shortens bleeding time [6].
It has also proved to be beneﬁcial as adjunctive therapy in
major upper GI bleeding including that occurring in dialysis
patients [7].
Successful TA therapy of life-threatening hematuria in
PCKD has been reported previously in a single patient [8].
TA was given at a dose of 20mg/kg IV followed by 20mg/kg
orally every 2 days for 2 months.
In our case TA stopped bleeding within 24–36 hours on
each of four occasions. There were no signiﬁcant side eﬀects
apart from mild nausea with the third treatment. The nausea
on this occasion may be due to the use of TA at a higher
dose on the ﬁrst day. In addition it could have been due
to reduced renal function with transient uremia. In all four
episodes kidney function either stabilized or improved after
TA therapy. This is probably due to correction of a prerenal
element since TA has no direct eﬀect on kidney function in
patients with chronic renal impairment [6].International Journal of Nephrology 3
Renal hematuria is considered a contraindication for
TA treatment, because it may cause bladder and ureteral
occlusion by clots. This complication can be successfully
resolved with a double J stent [8]. In addition there are
reports of acute renal cortical necrosis after use of TA. In
one case, a 37-year-old man with baseline serum creatinine
of80µmol/LreceivedhighdoseTAtotreathemoptysis(3gm
IV daily for ﬁve days). Serum creatinine was 610µmol/L on
the 6th day [9]. In another case a 21-year-old man with
hemophilia A who received TA for epistaxis at the same high
dose (3gm iv daily for 4 days), 3 days later his creatinine
was 336µmol/L and after 6 days serum creatinine has risen
to 716µmol/L [10]. We believe that this complication may
be due to the use of high dose TA over several days.
Another possible side eﬀect of TA is increased risk of
thrombosis. However,In a recent review, Tengborn questions
the association of TA use and thrombosis given the lack of
excess cases in TA studies involving cardiac surgery, total
knee and hip arthroplasty, bleeding disorders of pregnancy,
and menorrhagia [11]. This risk is sometimes thought to
be higher in hemophiliac patients with hematuria. However
in our case the patient had no known history of bleeding
disorder.
TA accumulates in the presence of reduced kidney func-
tion as it is excreted by glomerular ﬁltration [12]. The usual
dose is 10mg/kg three or four a times a day. Andersson
et al. recommended dose reduction of TA in patients with
renal impairment as follows: for serum creatinine of 120–
250µmol/L 10mg/kg intravenously twice daily; for serum
creatinine of 250–500µmol/L 10mg/kg intravenously once
daily; for serum creatinine above ≥500µmol/L 10mg/kg
intravenously every 48hr [12]. Similar doses have been
successfully used in dialysis patients with upper GI bleeding
[7].
Our patient received a range of TA doses from 15mg/kg
intravenouslythreetimesadayto10mg/kgonceadayorally;
all were equally eﬀective. We recommend the use of oral TA
in the lowest possible eﬀective dose for the shortest duration
to reduce the risk of adverse eﬀects. For our patient this
turned out to be 10mg/kg once a day orally for 3 days. It
is possible that TA therapy of less than three days duration
m i g h tb ej u s ta se ﬀective but this has not been examined.
Earlyuse ofTAathomebypatientswithrecurrent hematuria
with PCKD would be very cost eﬀective if hospitalization
could be prevented.
5.Conclusion
TA can be used safely in some patients with chronic renal
impairment and PCKD to treat severe hematuria poorly
responsive to conventional therapy. TA dose can be given
orally or IV; dose adjustment for renal impairment is impor-
tant. TA therapy may preserve renal function indirectly in
PCKD by avoidance of nephrectomy.
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